Gadeta is a clinical stage biotechnology company developing a first-in-class cellular immunotherapy for the treatment of cancer, using a number of proprietary manufacturing and T-cell engineering technologies. The Company is pioneering the development of αβ T-cells engineered to express defined γδ T-cell receptors that can specifically recognize cancer cells, eliminate them, and spare healthy cells. Gadeta has a pipeline of product candidates in development for the treatment of haematologic malignancies and solid tumours.

The Gadeta office and laboratory is located in the Bio Incubator next to the UMCU and collaborates with top-tier international scientists to achieve its goals.